Pharmacogenetic of Doxorubicin in HCC.
1 other identifier
observational
81
1 country
1
Brief Summary
The study included 81 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results. Every research participant take part in the experiment and provided written informed consent.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2023
CompletedFirst Submitted
Initial submission to the registry
March 9, 2024
CompletedFirst Posted
Study publicly available on registry
March 15, 2024
CompletedMarch 28, 2024
March 1, 2024
3 years
March 9, 2024
March 27, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
GSTP1
Genotyping
1 year
CYP2B6
Genotyping
1 year
Study Arms (1)
HCC patients
Each of the patients was given Doxorubicin and followed up for one year.
Interventions
each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
Eligibility Criteria
100 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
You may qualify if:
- When diagnosing the patient with HCC, the guidelines provided by the American Association for the Study of Liver Diseases (AASLD) were adhered to.
- Be above 20 years old.
- Individuals with intact organs.
- There is no cure for HCC in surgery, microwave treatment, or radiofrequency ablation.
You may not qualify if:
- The patients refused to sign the formal consent.
- Be more than 75 years old.
- There is a notable case of portal vein thrombosis.
- Spreads beyond the liver.
- Encephalopathy of the liver.
- Present sickness.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rehab Weridalead
- King Saud Bin Abdulaziz University for Health Sciencescollaborator
- King Abdulaziz Universitycollaborator
Study Sites (1)
King Abdullah bin Abdulaziz University Hospital
Riyadh, Saudi Arabia
Related Publications (1)
Shilbayeh SAR, Abd El-Baset OA, Alshabeeb MA, Alanizi AH, Khedr NF, Werida RH. The Influence of CYP2B6, GSTP1, and SLCO1B1 Star Allele-Predicted Phenotypes and CBR1 Genetic Variants on Effectiveness Outcomes in Patients With Hepatocellular Carcinoma Receiving Doxorubicin via Transarterial Chemoembolization. Pharmacol Res Perspect. 2025 Jun;13(3):e70114. doi: 10.1002/prp2.70114.
PMID: 40405401DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Sireen Shilbayeh, Prof.
Princess Nourah Bint Abdul Rahman University
- STUDY DIRECTOR
Mohammad A. Alshabeeb
King Saud Bin Abdulaziz University for Health Sciences
- PRINCIPAL INVESTIGATOR
Abdalrhman H Alanizi
King Abdulaziz University
- STUDY DIRECTOR
Naglaa Khedr, Prof.
Tanta University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
March 9, 2024
First Posted
March 15, 2024
Study Start
January 1, 2021
Primary Completion
December 15, 2023
Study Completion
December 30, 2023
Last Updated
March 28, 2024
Record last verified: 2024-03